AstraZeneca and Daiichi Sankyo dosed the first patient in the TROPION-Urothelial04 Phase 3 clinical trial. The study evaluates Datroway (datopotamab deruxtecan) as an adjuvant treatment for muscle-invasive urothelial cancer. This trial targets patients at high risk of recurrence following surgical resection.
This marks the second pivotal study for Datroway in this cancer type. Daiichi Sankyo discovered the antibody-drug conjugate and co-develops it with AstraZeneca. Datroway represents a key asset in both companies' oncology pipelines. The companies are assessing its potential in earlier lines of treatment to improve patient outcomes.